	son & Johns care / Drug Ma	son (JNJ) anufacturers - G	General					KRover
\$167.60) \$2.52 (1.	53%) as of Frid	day's close	Cap (\$M USD) \$440,650	P/E 24.4	EPS (1Y) 3.3%	Dividend \$4.52	Last Filing 06/30/22
52-wk Rang \$155.72	je	\$186.69		Sales (\$M) 95,588	Forward P/E 15.8	Sales (1Y) 7.2%	Div. Yield 2.7%	Next Earnings 10/18/22
JNJ 167.60 ((+4.0%) Heal	Sep 16, 2021 - thcare 235.80 (-7.6		00 3873.33 (-12.0%	my	- 13.9% by JN. 11. - 0.0% The out	15.9% in the p J has outperfor 5% in the past e Healthcare s	med its sector by year.
Buy	T CONSENS		us rating is unch	anged from 1 month ago.	Strong Bu	iy iy 1		7
Strong Buy	Buy	Hold	Sell	Strong Sell	Но	Id ell 0		8
QUANTI	TATIVE SCOF	RES						
Fair Value Margin of S	\$193.7 Safety 16%			The Margin of Safe between a compar current price. See	ny's Fair Value ar			╡1 warning ⊨ Details on Page 8
Value Score 81	P/E, P/S, P/TB (Predictability. P/	ur value score look Price/Tangible Boo S and P/TB are co etrics are compared	ok) and EPS mpared within a	Score	profitability an quality compa	e: Our quality s ad balance she nies using RO est Coverage, a	et metrics to fir IC, Net Margin	nd high , Gross
Growth Score 84	history and the f	Our growth score I forward estimates for a, ranking the best of	or EBITDA, Sale	es, Score	in favor by an periods over t	core: Our senti alyzing Short Iı he last year, Pı 2-wk High and	nterest, returns rice vs. 52-wk	in key High,

BUSINESS SUMMARY

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total revenue is generated in the United States.

Employees 144,300

Homepage www.jnj.com

Headquarters New Brunswick, NJ


Healthcare / Drug Manufacturers - General

VALUATION SUMMARY

	JNJ	Industry	S&P 500
Value Score	81	73	75
Price / Earnings	24.4	18.5	20.4
Price / Sales	4.7	3.7	2.3
Price / Free Cash Flow	22.4	16.5	20.7
Price / Book	5.8	4.7	4.1
Price / Tangible Book	-	-	100+
EV / EBITDA	15.9	12.7	17.2
EPS Predict. Pctl.	86	75	70
Piotroski F Score	9	5	8
5-Year P/E Range	21.1		100+
5-Year P/B Range	4.5		7.2
5-Year P/S Range	3.7		5.7

GROWTH SUMMARY

	JNJ	Industry	S&P 500
Growth Score	84	76	78
Sales Growth			
Sales Growth Next Year	3.9%	-2.2%	7.6%
Sales 1-Year Chg (%)	7.2%	17.5%	15.2%
Sales 3-Year Avg (%)	5.5%	8.7%	16.9%
Sales 5-Year Avg (%)	5.7%	6.2%	14.3%
EPS Growth			
Next Yr. Growth Est.	5.2%	1.5%	10.1%
EPS 1-Year Chg (%)	3.3%	26.4%	16.6%
EPS 3-Year Avg (%)	4.4%	9.6%	13.1%
EPS 5-Year Avg (%)	3.1%	8.1%	13.4%



PEERS ANALYSIS SUMMARY

Ticker	Company	Cap (\$M USD	P/E	Div. Yield	1M Return	1Y Return	Margin of Safety	Value Score	Growth Score	Quality Score
JNJ	Johnson & Johnson	\$440,650	24.4	2.7%	0.7%	4.1%	16%	81	84	96
LLY	Eli Lilly	\$293,499	49.3	1.3%	-0.5%	35.6%	-8%	67	88	93
PFE	Pfizer	\$258,336	9.0	3.5%	-7.7%	6.9%	10%	91	68	97
ABBV	AbbVie	\$254,711	20.4	3.9%	1.1%	38.8%	6%	80	72	88
MRK	Merck & Co	\$222,219	13.4	3.2%	-2.4%	26.2%	14%	83	74	96
AZN	AstraZeneca	\$178,911	-	2.5%	-13.0%	5.0%	4%	69	81	59
NVS	Novartis	\$177,597	7.9	4.1%	-6.0%	-0.5%	-15%	89	73	98
BMY	Bristol-Myers Squibb	\$152,713	23.8	3.0%	-3.5%	20.5%	23%	77	92	86
AMGN	Amgen	\$123,643	19.7	3.4%	-8.0%	9.9%	32%	83	80	90
SNY	Sanofi	\$102,780	15.5	4.3%	-8.9%	-12.0%	35%	81	84	90
GILD	Gilead Sciences	\$82,220	20.1	4.5%	0.0%	-3.7%	27%	83	53	86
ZTS	Zoetis	\$73,638	35.7	0.8%	-8.4%	-21.9%	8%	72	92	93

Healthcare / Drug Manufacturers - General



PROFITABILITY SUMMARY

	JNJ	Industry	S&P 500
Quality Score	96	84	77
Gross Margin	67.9%	68.6%	30.2%
Operating Margin	25.4%	24.7%	14.8%
Net Margin	19.2%	20.1%	11.8%
Return on Assets	10.3%	11.1%	8.7%
Return on Equity	24.1%	31.0%	35.2%
ROIC	17.0%	18.2%	20.1%

RETURNS SUMMARY

	JNJ	Industry	S&P 500
Sentiment Score	94	56	54
5-Day Return	1.1%	-1.4%	-4.4%
1-Month Return	0.7%	-4.7%	-9.7%
YTD Return	-0.1%	-6.9%	-17.8%
1-Year Return	4.1%	-0.4%	-11.8%
3-Year Return	39.9%	28.8%	36.2%
5-Year Return	42.2%	42.2%	68.9%
Beta 1-Year	0.29	0.31	0.99



DIVIDEND

	JNJ	Industry
Dividend Yield	2.7%	3.0%
Payout Ratio	61.8%	56.2%
TTM Yield	2.6%	
Dividend Per Share	\$4.52	\$3.65
Div. 1Y Chg (%)	6.6%	51.3%
Div. 3Y Avg (%)	6.0%	8.0%
Div. 5Y Avg (%)	6.1%	6.8%
Cons. Growth Years	10+	1
Div. Coverage Ratio	1.6	1.8

DEBT & EQUITY

Current Ratio	1.4
Quick Ratio	1.2
Price	\$167.60
Net Cash Per Share	-\$0.20
Equity Per Share	\$29.04
Debt / Equity	0.4
Solvency Ratio	35%
Interest Coverage	160.3
Short % of Float	0.4%
Altman Z-Score	4.7

ANALYST REVISIONS

MEAN ESTIMATE TREND

Current Quarter E	PS	Next Quarter EPS	S		Cur Qtr	Next Qtr	Cur Year	Next Year
# Up Last 30 days	0.00	# Up Last 30 days	0.00	Latest	\$2.52	\$2.27	\$10.07	\$10.59
# Down Last 30 days	1.00	# Down Last 30 days	0.00	30 Days Ago	\$2.52	\$2.27	\$10.07	\$10.59
Mean Estimate	2.27	Mean Estimate	2.52	90 Days Ago	\$2.66	\$2.35	\$10.27	\$10.89
% Change (30 Days)	-	% Change (30 Days)	-	% Change (90 Days)	-5.3%	-3.4%	-1.9%	-2.8%

Healthcare / Drug Manufacturers - General

EARNINGS SURPRISES

Earnings surprise is the difference between a company's announced earnings and the average analyst estimated value. Surprises typically causes the stock price to jump and are often followed by more of the same surprise type.

Surprise Summary (Last 12 Quarters)

Surprise Type	Amount	Percent
Positive Quarters (> 2%)	9	75.0%
Negative Quarters (< 2%)	0	-
In-Line Quarters (within 2%)	3	25.0%

RISK

	JNJ	Industry	S&P 500
Best Monthly Return (5Y)	16.5%	11.6%	17.9%
Worst Monthly Return (5Y)	-11.7%	-7.8%	-16.4%
Beta 1-Year	0.29	0.31	0.99
Volatility 1-Year	0.17	0.14	0.21
Volatility 1Y Pctl.	16	-	-
Max Drawdown 1-Year	-13.3%	-21.2%	-23.5%
Max Drawdown 3-Year	-27.8%	-30.2%	-33.9%
Max Drawdown 5-Year	-27.8%	-32.7%	-33.9%

SEASONALITY



5-YEAR RELATIVE PERFORMANCE VS S&P 500

Relative to the S&P 500 baseline, JNJ has underperformed the S&P 500 by -27.5% in the past 5 Years.

JNJ has underperformed its sector by -22.0% in the past 5 Years.

The Healthcare sector has underperformed the market by -5.5% in the past 5 Years. Dividend Adjusted Return Sep 15, 2017 - Sep 16, 2022



Surprise Detail (Last 6 Quarters)

Surprise Type	Announce Date	Period End Date	Actual EPS	Est. EPS	Surprise (%)
In-Line	07/19/22	06/30/22	\$2.59	\$2.57	0.8%
Positive	04/19/22	03/31/22	\$2.67	\$2.60	2.8%
In-Line	01/25/22	12/31/21	\$2.13	\$2.12	0.5%
Positive	10/19/21	09/30/21	\$2.60	\$2.37	9.7%
Positive	07/21/21	06/30/21	\$2.48	\$2.28	8.8%
Positive	04/20/21	03/31/21	\$2.59	\$2.31	12.1%

79

Healthcare / Drug Manufacturers - General

Stock Rover Stock Report | September 17, 2022

Overall Rating vs. Peers Ratings scores are relative to industry groups. They compare key metrics to rank stocks vs. their competitors. For example, higher growth than peers will score high even when the absolute growth is below the market average.

Growth vs	Peers							
Ticker	Company	Growth Rating vs. Peer	Sales QoQ Chg.	Eps QoQ Chg.	Sales Growth Next Y.	Sales 1Y Chg (%)	Sales 3Y Avg (%)	Sales 5Y Avg (%)
MRK	Merck & Co	99	28.0%	222.9%	-2.1%	13.5%	8.8%	7.4%
ABBV	AbbVie	89	4.5%	21.4%	-6.2%	6.7%	20.7%	16.5%
LLY	Eli Lilly	81	-3.7%	-31.4%	5.9%	8.8%	5.5%	5.7%
NVS	Novartis	67	-1.6%	-39.8%	2.9%	2.4%	-0.6%	1.4%
JNJ	Johnson & Johnson	52	3.0%	-23.4%	3.9%	7.2%	5.5%	5.7%
Valuation	e Poore							

valuation v	31 6613								
Ticker	Company	Valuation	P/E	Forward PEG P/E Trailing		P/S	P/B	5Y P/E Range	
NVS	Novartis	Rating vs. Peer	7.9	12.1	0.3	3.4	2.8	7.6 33.4	
MRK	Merck & Co	67	13.4	11.8	0.5		5.1		
LLY	Eli Lilly	44	49.3	32.2	2.2		34.4		
	,							21.3	
ABBV	AbbVie	43	20.4	12.1	1.7	4.5		13.9 44.9	
JNJ	Johnson & Johnson	35	24.4	15.8	8.0	4.7	5.8	21.1 100+	

Efficienc		D
HTTICIANC	/ \/e	Paare
LINGICIUS	/ / 3	

Ticker	Company	Efficiency Rating vs. Peer	Gross Margin	Operating Margin	Net Margin	5Y ROE Range	5Y ROA Range
MRK	Merck & Co	100	70.4%	33.9%	29.0%	4.1%	1.6%
LLY	Eli Lilly	96	76.0%	29.7%	19.6%	-1.8% 319.1%	-0.5% 21.2%
NVS	Novartis	94	70.6%	20.6%	43.5%	9.4%	4.9%
ABBV	AbbVie	88	70.5%	32.2%	22.0%	-190.2%	3.1%
JNJ	Johnson & Johnson	87	67.9%	25.4%	19.2%	2.0%	0.8%

Financial Strength vs Peers


	J							
Ticker	Company	Financial Strength Rating vs. Peers	Debt / Equity	Interest Coverage	Quick Ratio	Intangibles %	Solvency Ratio	Short % of Float
JNJ	Johnson & Johnson	88	0.4	160.3	1.2	43.1%	35%	0.4%
NVS	Novartis	81	0.5	31.7	1.1	50.8%	57%	-
MRK	Merck & Co	77	0.7	21.9	1.2	40.8%	39%	0.8%
ABBV	AbbVie	72	5.0	7.2	0.8	72.5%	22%	0.7%
LLY	Eli Lilly	67	2.0	19.8	0.9	24.2%	24%	0.6%

Dividends v	vs Peers							
Ticker	Company	Dividends Rating vs. Peer	Div. Yield	TTM Yield	Price	Div. Per Share	Consecutive Div. Growth Years	Payout Ratio
NVS	Novartis	98	4.1%	4.1%	\$80.65	\$3.33	2	32.4%
ABBV	AbbVie	82	3.9%	3.8%	\$144.06	\$5.64	8	76.3%
MRK	Merck & Co	60	3.2%	3.2%	\$87.72	\$2.76	10+	41.5%
JNJ	Johnson & Johnson	50	2.7%	2.6%	\$167.60	\$4.52	10+	61.8%
LLY	Eli Lilly	34	1.3%	1.2%	\$308.89	\$3.92	7	58.1%

Momentum	n vs Peers									
Ticker	Company	Momentum	1M	3M	6M	YTD	1Y	Beta	Volatility	Price vs
		Rating vs. Peer	Return	Return	Return	Return	Return	1Y	1Y	52-wk High (%)
LLY	Eli Lilly	92	-0.5%	7.6%	12.5%	13.0%	35.6%	0.60	0.27	92.1%
MRK	Merck & Co	89	-2.4%	4.2%	14.1%	17.4%	26.2%	0.28	0.24	91.6%
ABBV	AbbVie	87	1.1%	4.5%	-6.0%	9.4%	38.8%	0.32	0.20	81.9%
JNJ	Johnson & Johnson	80	0.7%	-0.8%	-2.7%	-0.1%	4.1%	0.29	0.17	89.8%
NVS	Novartis	69	-6.0%	-1.5%	-4.7%	-4.0%	-0.5%	0.36	0.18	85.6%

Healthcare / Drug Manufacturers - General

DIVIDEND DETAIL



CALENDAR YEAR DIVIDEND HISTORY

Year	Date	Pay Date	Text	Amount
2022 Dividends				\$3.32
	08/22/22	09/06/22	Regular	\$1.13
	05/23/22	06/07/22	Regular	\$1.13
	02/18/22	03/08/22	Regular	\$1.06
2021 Dividends				\$4.19
	11/22/21	12/07/21	Regular	\$1.06
	08/23/21	09/07/21	Regular	\$1.06
	05/24/21	06/08/21	Regular	\$1.06
	02/22/21	03/09/21	Regular	\$1.01
2020 Dividends				\$3.98
	11/23/20	12/08/20	Regular	\$1.01
	08/24/20	09/08/20	Regular	\$1.01
	05/22/20	06/09/20	Regular	\$1.01
	02/24/20	03/10/20	Regular	\$0.95
2019 Dividends				\$3.75
	11/25/19	12/10/19	Regular	\$0.95
	08/26/19	09/10/19	Regular	\$0.95
	05/24/19	06/11/19	Regular	\$0.95
	02/25/19	03/12/19	Regular	\$0.90
2018 Dividends				\$3.54
	11/26/18	12/11/18	Regular	\$0.90
	08/27/18	09/11/18	Regular	\$0.90
	05/25/18	06/12/18	Regular	\$0.90
	02/26/18	03/13/18	Regular	\$0.84

UPCOMING DIVIDEND	
Ex-Dividend Date	08/22/22
Payment Date	09/06/22
Amount	\$1.13
Туре	Regular

DIVIDEND RATE	
Regular Dividend	\$1.13
Annual Dividend Rate	\$4.52
Annual Dividend Yield	2.7%
Trailing 12 Months Dividends	\$4.38
Trailing 12 Months Yield	2.6%

STATISTICS	
Payout Ratio	61.7%
Dividend Coverage Ratio	161.9%
Consecutive Growth Years	10+
3 Year Growth Rate	6.0%
5 Year Growth Rate	6.1%
10 Year Growth Rate	6.4%

Healthcare / Drug Manufacturers - General

Stock Report | September 17, 2022

USD in Millions	Chart	2017	2018	2019	2020	2021	TTM	CAGR
Income Statement								
Revenue		76,450	81,581	82,059	82,584	93,775	95,588	4.9%
Operating Income		18,897	21,175	20,970	19,914	24,547	24,241	5.4%
Net income		1,300	15,297	15,119	14,714	20,878	18,366	75.5%
Earnings per share diluted		\$0.47	\$5.61	\$5.63	\$5.51	\$7.81	\$6.87	76.7%
Average shares diluted		2,745	2,729	2,684	2,671	2,674	2,672	-0.6%
P/E Ratio		24.3	217.4	27.8	24.8	25.6	24.4	0.1%
Balance Sheet								
Cash		18,296	19,687	19,287	25,185	31,608	32,568	13.0%
Current assets		43,088	46,033	45,274	51,237	60,979	63,847	8.7%
Net Property, Plant and Equipm		17,005	17,035	17,658	18,766	18,962	18,354	1.6%
Working Capital		12,551	14,803	9,310	8,744	15,753	19,026	9.2%
Net Debt		16,285	10,793	8,409	10,081	2,143	29	-73.99
Stockholders' Equity		60,160	59,752	59,471	63,278	74,023	76,357	5.29
Cash Flow								
Operating Cash Flow		21,056	22,201	23,416	23,536	23,410	23,582	2.49
Cap Ex		-3,279	-3,670	-3,498	-3,347	-3,652	-3,632	2.20
Free Cash Flow		17,777	18,531	19,918	20,189	19,758	19,950	2.5
Free Cash Flow per share		\$6.48	\$6.79	\$7.42	\$7.56	\$7.39	\$7.47	3.19
⁷ Profitability								
Operating Margin		24.7%	26.0%	25.6%	24.1%	26.2%	25.4%	0.59
Return on Assets		0.8%	10.0%	9.6%	8.4%	11.5%	10.3%	71.09
Return on Equity		2.2%	25.6%	25.4%	23.3%	28.2%	24.1%	66.89
Return on Invested Capital		1.7%	16.9%	17.0%	15.9%	20.4%	17.0%	63.19
Dividends								
Dividends Per Share		\$3.32	\$3.54	\$3.75	\$3.98	\$4.19	\$4.52	6.8
Dividend Yield		2.4%	2.8%	2.6%	2.6%	2.5%	2.7%	2.5
Dividend Growth		-	6.6%	5.9%	6.1%	5.3%	10.5%	13.3
Dividend Coverage		0.1x	1.6x	1.5x	1.4x	1.9x	1.6x	67.09

VALUATION & PROFITABILITY HISTORY

Date >		TTM	1 Yr	2 Yrs.	3 Yrs.	4 Yrs.			
			Ago	Ago	Ago	Ago			
Price / Earnings		24.4	29.2	23.1	21.5	100+			
Price / Cash Flow	1.1	19.0	18.2	17.1	16.0	17.6			
Price / Book	. II.	5.8	6.6	6.4	5.6	5.9			
Price / Tangible B		-	-	-	-	-			
Price / Sales	1.1.	4.7	5.2	4.8	4.3	4.9			
EV / EBITDA	1.10	15.9	16.4	18.0	13.4	16.9			
Dividend Yield	_1	2.7%	2.6%	2.7%	2.9%	2.6%			
Shareholder Yield	_ I	3.6%	3.2%	3.8%	5.6%	3.2%			
Gross Margin	_0_0	67.9%	67.0%	65.7%	66.7%	65.7%			
Net Margin		19.2%	19.9%	18.9%	20.1%	1.7%			
Return on Assets		10.3%	10.1%	9.6%	10.5%	0.9%			
Return on Equity		24.1%	25.5%	24.1%	26.9%	2.2%			
ROIC	_1000	17.0%	17.5%	16.5%	18.9%	2.5%			

Healthcare / Drug Manufacturers - General

Stock Report | September 17, 2022

WARNINGS								
Name	Severity	Details						
GAAP Earnings vs. Pro Forma	Low 📜	Official EPS: \$1.80; Announced EPS: \$2.59						

The GAAP compliant earnings that the company filed with the SEC are less than the pro-forma earnings they announced to the press. Pro-forma earnings can exclude special one-time charges but some distressed companies post these "one-time" charges quarter after quarter.

REPORT TIPS

Metric Definitions

Metric descriptions are available at stockrover.com/help/metrics/metric-overview

Quantitative Scores

Our scores analytics is to offer our concise analysis of a stock in powerful, but easy to digest format. Each of the composite score metrics are designed to use the best available accounting practices as well as source data from SEC filings. The scores are computed for a company vs. the market as a whole. **Fair Value**

Fair value performs a forecasted discounted cash flow analysis of a company to determine the company's intrinsic value based on the expected future cash flows the company will produce. It basically determines what a company is worth based on how much cash flow it is expected to generate for you in the future, taking into account the time value of money and the predictability of those forecasted cash flows.

Peers

Peer ratings are computed from raking companies in the same

DISCLAIMER

Financial Statements and Historical Prices Provided by Morningstar. © 2022 Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Stock Rover and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely.

The information provided does not constitute investment advice, nor does it constitute a recommendation to buy or sell any security. Stock Rover LLC and its content providers are not responsible for any losses resulting from trading decisions arising from any use of this information. Past performance is no guarantee of future results.

The information provided is as of the date written and is subject to change without notice

Additional data provided by Zacks, Intrinio, Quandl, Yodlee, IEX Cloud